Alon Ben-Noon
@NoonAlon
Followers
1,534
Following
2,703
Media
82
Statuses
278
Leading NeuroSense Therapeutics (Nasdaq: $NRSN), a Clinical stage Biotech company, accelerating therapies for ALS and Neurodegenerative diseases.
Joined January 2020
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
SB19 ROCKS ARANETA
• 195027 Tweets
Eminem
• 174262 Tweets
NuNew x Poncheewan
• 142301 Tweets
#音楽の日
• 128707 Tweets
#Mステ
• 82432 Tweets
#それスノ
• 79920 Tweets
Githurai
• 75126 Tweets
LAST FOREVER
• 68525 Tweets
NiziU
• 42860 Tweets
キングダム
• 39531 Tweets
#金スマ
• 32234 Tweets
サヨナラ
• 30538 Tweets
TALK WITH MEW TUL
• 22130 Tweets
chamber5
• 18699 Tweets
ブレイバーン
• 15044 Tweets
Cenk Tosun
• 13012 Tweets
Kroi
• 12333 Tweets
An honor to meet and work with Brian Wallach, a true fighter, intelligent and creative, paving a way towards an effective therapy with his wife, Sandra. A power couple. battling ALS, defeating ALS.
10
61
2K
$nrsn enters Q2 with the launch of a PK study in the US, using a novel formulation of PrimeC:
11
68
649
Spirit of ALS Patient Drives NeuroSense Mission to Bring PrimeC to Market.
I love and relate to this article title.
5
97
541
$nrsn
Very excited about this:
And thanking all our collaborators for this amazing achievement
2
35
387
In the next few days I'll be discussing $BCLI Adcomm and why the path of $NRSN is not only distinct but also exceptionally unique. 🧠 Mark your calendars for December when we unveil the Paradigm results. Stay tuned!
6
10
174
$nrsn PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model
1
5
156
Great Talk at the AD/PD 2022, given by Dr. Shiran Salomon-Zimri, the Head of our Scientific Program.
Shiran presented a novel approach to treat ALS by tackling multiple MoAs in parallel and the potential clinical outcomes this may lead to.
Well Done, we are very proud of you!
0
26
148
$nrsn - Sharing recorded corporate highlights from Q1 and future plans:
2
10
118
Nice article on $NRSN successful clinical trial in ALS.
PrimeC - Safe, well tolerated and slows down disease progression 💊
#ALS
#FightingALS
#ALStherapy
4
15
116
@BarashiKinneret
@Ain_li_Kochot
@netanyahu
@ohadh1
הבושה הגדולה היא שלך ושל שופרות כמותך, שהשכר שלהם תלוי בבן אדם אחד בזוי.
איזה עולב.
2
0
115
$nrsn Breaking News!
We are pleased to share that the pre-defined Per Protocol analysis of the top-line Phase 2b PARADIGM trial results revealed a statistically significant 37.4% difference in ALSFRS-R in patients treated with PrimeC vs. placebo, demonstrating PrimeC’s potential
8
15
96
We are pleased to share that the FDA has cleared the protocol for PARADIGM, an ALS Phase 2b clinical trial. This milestone paves the way for patient enrollment to commence in the US at leading ALS centers.
*Please share with the ALS community*
6
32
101
Can we predict the future?
To some extent we can, given reliable models that validate one another.
3
2
73
$nrsn glad to share these news
0
6
68
Join us in spreading Hope for those affected by ALS! 🗣️
In December, NeuroSense will unveil the clinical Top-line results of the Paradigm study, marking a major turning point in the fight against ALS. We're committed to sharing all results from this groundbreaking clinical trial
8
14
65
I love this photo
The additional coverage for our key patent further confirms the novelty of our approach of combining two drugs to act in synergy to improve the way that ALS is treated.
1
3
49
Phase IIa Study Results presented at Four International Conferences
The presentations are focused on key clinical findings from which showed promising clinical outcomes together with significant changes in ALS-related biomarkers.
3
6
44
Great news for NRSN !
1
5
34
A very important milestone NRSN achieved - an FDA IND Clearance in the US, boosting the clinical program to potentially bring PrimeC faster to patients in need.
Thanks to the devoted team of NeuroSense Therapeutics for this impressive achievement!
3
11
36
Key points:
1. Paradigm is powered to show changes in ALS-related Biomarkers.
2. Clinical efficacy, the secondary endpoint, exceeded expectations when it showed 29% in the ALSFRS-r. The expectation was to observe a change higher than 15% with a P< 0.3 - and yet PrimeC achieved
2
4
22
Tomorrow!
1
4
22
$nrsn
Exciting major ALS discovery by the Justin Ichida lab at USC, in an independent, non-sponsored research.
PrimeC Performed Favorably in comparison to approved and experimental ALS therapies.
courtesy of Dr. Justin Ichida
4
6
21
Great news for Italian people who suffer from ALS - very soon NeuroSense Therapeutics will commence the PARADIGM study in Italy.
1
4
20
So proud of the $nrsn team and thankful for our collaborators -
This achievement couldn't have been done without many leading experts, clinicians and researchers in the ALS field, all with the aim to advance an effective therapy for people with ALS
1
4
18
Happy to share these great news - to the ALS community, but also for Israel, as NeuroSense Therapeutics is an Israeli company.
2
1
19
Thanks for leading the The
@alsassociation
with a great passion and care.
Brainstorming on how to expedite the development of effective therapies and assuring All patients have access, is a mutual goal and the outcome may affect so many lives.
Looking forward to advancing this.
9
2
17
Great visit yesterday at the Cleveland Clinic with Amazing people, Top-Tier clinicians and researchers.
Thank you
@JustinLathia
for hosting us so nicely and for a super interesting, intensive and efficient day.
@NeurosenseT
1
0
15
Glad to meet old and new friends at the Cantor Fitzgerald Neurology&Psychiatry conference in SF.
Thanks to Charles C. Duncan for the invitation to participate in the ALS panel.
0
2
14
Proud of Dr. Ferenc Tracik, NeuroSense Chief Medical Officer who gave an excellent presentation at the ALS Summit event in Boston this week, covering science, clinical study design and $nrsn story.
1
1
12
Good news from Israel, Italy and Canada:
One month away from results.
0
2
14
$nrsn - This is a great milestone, achieved thanks to our amazing collaborators and the amazing team at NeuroSense:
0
3
13
The Head of ALS program at NeuroSense, Avital Pushett, with the ALS world-renowned clinician, and chair of NeuroSense SAB, Prof. Jeremy Shefner.
1
2
13
$nrsn
With our current cash position, we expect to complete preclinical studies for Alzheimer's and Parkinson's diseases and, most importantly complete our ALS Phase IIb study, leading to a potential inflection point in value for our Company.
0
1
12
$nrsn - Delighted to share that the first patient has been enrolled in PARADIGM, our ALS Phase IIb clinical trial, a milestone demonstrating NeuroSense Therapeutics long-term commitment to this critical unmet need.
0
0
13
Bruce, my hairstyle Bro.
FTD is a neurodegenerative disease, same as Alzheimer's, same as ALS.
All related.
NeuroSense Therapeutics is among the few that took the challenge to deal with these fatal diseases.
3
1
13
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
We are grateful to the participants living with ALS, their families, and the study investigators for their commitment to the PARADIGM trial and for taking part in our mission.
0
4
13
The Cantor Neurology and Psychiatry Conference, in San Francisco, on the conference's ALS panel, titled:
New Treatment Paradigm with More MoAs On the Way?
1
0
13
One Team, One soul
One prize, One Goal
Advancing effective treatments for ALS and other neurodegenerative diseases.
NeuroSense Therapeutics
0
1
13
Collaborating with organizations who are passionate about science and genuinely caring for patients in need and wisely advancing therapies, is what makes us better.
Thank you
@indunavar
for your pioneering spirit
@EverythingALS
1
4
12
2020 is going to be an exciting year for NeuroSense Therapeutics and a hopeful one for the ALS community, as PrimeC, which targets two fundamental mechanisms underlying the pathogenesis of ALS, will be provided to dozens of ALS patients.
#ALS
#NeuroSense
2
4
9
This is a great day for the ALS community!
Relyvrio - FDA approved for ALS.
Congratulating people with ALS, their families and Amylyx, for doing an amazing work, providing another treatment option and importantly, also paving the way for an expedited development route for PrimeC.
0
0
12
Today is Lou Grehig's Day.
NeuroSense Therapeutics is proud to be fighting for people like Lou, who face this harsh reality with grace. We hope our drug, PrimeC, which entered
#PhaseIIb
#clinicaltrials
yesterday, will shift the paradigm and bring hope to people living with
#ALS
.
0
2
11
Dr. Ferenc Tracik, MD, NeuroSense Therapeutics Chief Medical Officer, will be presenting this week at the ALS Drug Development Summit in Boston.
'A Paradigm Shift to Target Complexity of ALS'
1
3
12
Wishing our friends at Amylyx good luck today at the FDA AdCom
1
1
11
New Year celebration (Jewish calendar).
Wishing a Happy Holiday to our friends, investors, collaborators and most importantly to people living with ALS, who inspire us to continue working toward a cure.
Thank you for being part of our journey.
Cheers to a successful year ahead!
0
0
10
$nrsn
I'm thrilled to share more exciting news - Now from the Alzheimer's front:
0
1
10
These are great news for people with SOD-1 ALS and for the ALS community! NfL as a biomarker which correlates with the clinical outcome and shows the promise of Tofersen treatment.
In a 9-0 vote, FDA advisors recommended the agency grant accelerated approval to Biogen’s drug for a rare, genetic form of ALS $BIIB
3
2
19
1
1
10
Great news for the ALS community: Qalsody
A new FDA approved treatment for ALS SOD1, a rare genetic form of the disease.
Well done to all the people involved @ Biogen and Ionis Pharmaceuticals, Inc.
1
2
10
October 7
September 11 is a date that will live forever in America as one of the saddest days. If you imagine a day that is 10 times more, that is what we are experiencing in Israel nowadays.
Reflecting on the horrifying events taking place now in Israel:
~ 1,000 innocent
2
0
11
In the realm of medical advancements, there's a pressing call for progress in the treatment of ALS.
With its impact on individuals and their families, finding an effective therapy isn't just a medical goal – it's a matter of compassion and hope.
0
2
11
Exactly 6 years ago, on January 31st, at 5:30pm Israel time, was the first time I met Shay Rishoni.
It was an inspirational meeting which led to the initiation of NeuroSense.
He leaves us with an immense legacy.
@shayrishoni
@Prize4Life
0
1
10
81 years since Lue Gehrig passed away due to ALS.
In many years since, nothing had changed, but for the last few years there was a major progress.
This is also accelerated.
0
0
9
Fortunate to call Ryan Watts a friend
Denali Therapeutics
NeuroSense Therapeutics
0
1
9
"With this toxicology study, we achieved another meaningful milestone in our PrimeC development program" Dr. Ferenc Tracik, Chief Medical Officer at $nrsn
0
2
9
$NRSN Breakfast Club - Proud of the team and the great achievements. Anticipating the near future milestones...
1
2
9
Missed posting these good news:
FDA Confirmation of $NRSN CMC Strategy
1
2
9
Alone we are rare, together we are strong.
* This slogan is a registered trademark of the National Organization for Rare Disorders
👩🦼👫👭🌈
1
2
8
At our Cambridge office - NRSN, Management & Board open discussions always lead to productive outcomes
1
0
9
$nrsn
Additional Great News:
European Medicines Agency Grants NeuroSense SME Status
0
1
8
Announcing Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US 🌈
0
1
8
NRSN on Nasdaq, now moving even faster towards an effective therapy for people with ALS.
NeuroSense Therapeutics Ltd. got listed on Nasdaq (under the ticker NRSN) and raised $12M. We keep on moving our development and deliver our promise to the patients.
All my appreciation to the devoted team that work tirelessly, advancing therapies to patients in need.
0
0
5
0
0
8
May - ALS Awareness Month:
1
2
8
5 Year ago Shay passed away, but not his legacy, not his spirit. We carry the torch and advance PrimeC's development towards a brighter future for people who suffer from ALS and their loved ones.
Shay Rishoni, March 2, 1966 - May 24, 2018
1
0
7
Excellent feedbacks and huge interest.
Thanks Dr. Shiran Zimri for presenting NeuroSense Therapeutics recent exciting findings.
1
1
7
The rhythm of the night, at the IsrALS Running for People with ALS event.
NeuroSense Therapeutics & next generation
1
1
7
Glad to participate and present at the Bio CEO & Investor Conference, on Feb 15th at the New York Marriott Marquis.
1
3
7
Fruitful collaborations are what drive science toward disruptive innovation that improve early diagnosis and treatment of unmet needs.
1
3
7
ALS awareness month.
We are aware. We are fighting.
While the Coronavirus around, taking attention and resources, we don't spare any effort.
Running two clinical trials in paralel and preparing for the next stage, until ALS patients will have a good solution available.
#ALS
1
2
5
NeuroSense Therapeutics has over 70% women, all are amazing people which create an enormous value.
International Women's day is every day at NeuroSense.
It's a privilege for me to be a part of this.
Here are few of NeuroSense Therapeutics inspiring women:
0
0
7
NeuroSense Therapeutics is inviting the Boston scientific community for an in-person meeting at NRSN Cambridge office location.
Thursday, Feb 17, at 09:00, One Broadway, Cambridge, MA
0
1
7
In preparation for our upcoming double-blind, placebo controlled clinical trial, we recently recruited two additional excellent team members, for operational execution.
They just happen to be women, bringing the NeuroSense team to a significant feminine majority!!! 🙂
0
0
6
The dedication and commitment of Cytokinetics ( $cytk ) and Robert Blum to the ALS community is admirable.
This wall in the office of the company emphasizes this in a genuine manner.
0
1
6
$nrsn
Results are in! Read more about our promising findings from a novel Parkinson's biomarker study-
0
1
5
we need to act faster, for the benefit of those who are still among us and their families.
ALS took my valentine of 38 years
@becky_mourey
♥️ today. My heart is broken. 😞 I hope her advocacy makes life a little easier for the next generation of ALS patients
#ENDALS
@iamalsorg
@alsone_official
95
57
1K
3
1
6
Today in Barcelona. Tomorrow - Friday, Dr. Zimri will present: "Breaking the Paradigm - PrimeC Novel Approached to ALS Therapy"
0
0
6
With a patient-centric approach, NeuroSense strives to be an active part of patient communities.
Involvement in the community is one of NeuroSense's values.
IsrALS
#community
#Running4ALS
0
2
6
Learn about the PARADIGM Clinical Study that is just about to start in the USA.
Thank you Indu Navar and the people from Everything ALS for your care to people who suffer from ALS, assuring to increase the community's knowledge of the available programs in the US.
0
0
6
We are very pleased to collaborate with
@NeuraLight
stellar team who are pioneering the development of digital oculometric biomarkers, which complement
@NeuroSense
extensive evaluation of biological markers of ALS.
#AI
#MachineLearning
0
1
6
Exactly 3 years ago this was published.
So much was advanced since then and hope in on the horizon.
Happy to say that Eti is still alive and didn't decline much.
0
1
5